Nucleotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Gonzalez became the executive chairman. In August 2024, AbbVie acquired neuroscience drugmaker Cerevel Therapeutics for $8.7 billion, in an attempt to expand its drug pipeline. In September 2024, AbbVie filed a lawsuit against BeiGene accusing it of stealing trade secrets to develop a competing therapy to treat blood and bone marrow cancers related to the growth of "B cells" after BeiGene hired a former longtime senior AbbVie scientist. In October 2024, AbbVie acquired Aliada Therapeutics for $1.4 billion to expand its neuroscience pipeline. In January 2025, AbbVie acquired Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune area, for $200 million. In the same month, AbbVie announced a $1.64 billion partnership with Neomorph to develop new molecular glue degraders for multiple targets across oncology and immunology, as well as a $1 billion partnership with Simcere Zaiming to develop an investigational drug candidate for multiple myeloma. In May 2025, AbbVie entered into a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease areas like neuroscience, immunology, and oncology. In August 2025, AbbVie acquired Bretisilocin, which is under development for the treatment of major depressive disorder, from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion. In January 2026, AbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over the next 10 years and lower Medicaid prices.
==== Formation of the neurotransmitter gamma-aminobutyric acid ==== A study conducted on the GABAergic neurons (i.e., nerve cells) in the neocortex of rat brains reported that the cytosolic form of the aspartate transaminase enzyme metabolizes α-ketoglutarate to glutamate which in turn is metabolized by glutamic acid decarboxylase to the inhibitory neurotransmitter gamma-aminobutyric acid. These metabolic reactions occur at the ends of the inhibitory axons of the GABAergic neurons and result in the release of gamma-aminobutyric acid which then inhibits the activation of nearby neurons.
==== 3000–3099 ==== Motor Vehicles (Tests) (Amendment) Regulations 1993 (S.I. 1993/3011) Public Service Vehicles (Conditions of Fitness, Equipment, Use and Certification) (Amendment) Regulations 1993 (S.I. 1993/3012) Goods Vehicles (Plating and Testing) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3013) Community Customs Code (Consequential Amendment of References) Regulations 1993 (S.I. 1993/3014) Statistics of Trade (Customs and Excise) (Amendment No. 2) Regulations 1993 (S.I. 1993/3015) Retirement Benefits Schemes (Restriction on Discretion to Approve) (Additional Voluntary Contributions) Regulations 1993 (S.I. 1993/3016) Advice and Assistance (Scotland) (Prospective Cost) Revocation Regulations 1993 (S.I. 1993/3017) Inverclyde Royal National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3018) Kirkcaldy Acute Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3019) Queen Margaret Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3020) Stobhill National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3021) Angus National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3022) Glasgow Royal Infirmary University National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3023) Renfrewshire Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3024) West Glasgow Hospitals University National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3025) Highland Communities National Health Service Trust (Establishment) Order 1993 (S.I.
==== Pancreatic cancer ==== First-in-human application of different αvβ6-integrin radiotracers has demonstrated that 68Ga-Trivehexin performed especially well in detecting pancreatic cancer, showing high uptake in tumor lesions and low background in the gastrointestinal tract (GI tract) (see image). Since its introduction, 68Ga-Trivehexin has been used predominantly for PET/CT imaging of pancreatic ductal adenocarcinoma (PDAC), for example, in single cases and two cohorts (12 and 44 patients, respectively) of suspected or known PDAC.
Sources: en.wikipedia.org
Acute intermittent porphyria Adrenoleukodystrophy (Schilder's disease) Alkaptonuria Aminolevulinic acid dehydratase deficiency porphyria (Doss porphyria, plumboporphyria) B-mannosidase deficiency Carotenosis Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome (CADASIL syndrome) Cerebrotendinous xanthomatosis Citrullinemia Congenital erythropoietic porphyria (Gunther's disease) Diabetic bulla (bullosis diabeticorum, bullous eruption of diabetes mellitus) Diabetic cheiroarthropathy Diabetic dermopathy (shin spots) Dystrophic calcinosis cutis Eruptive xanthoma Erythropoietic protoporphyria Fabry disease (Anderson–Fabry disease, angiokeratoma corporis diffusum) Familial alpha-lipoprotein deficiency (Tangier disease) Familial amyloid polyneuropathy Familial apoprotein CII deficiency Familial combined hyperlipidemia (multiple-type hyperlipoproteinemia) Familial defective apolipoprotein B-100 Familial dysbetalipoproteinemia (broad beta disease, remnant removal disease) Familial hypertriglyceridemia Farber disease (fibrocytic dysmucopolysaccharidosis, lipogranulomatosis) Fucosidosis Gaucher's disease Gout (podagra, urate crystal arthropathy, urate deposition disease) Hartnup disease (pellagra-like dermatosis) Hemodialysis-associated amyloidosis Hepatoerythropoietic porphyria Hereditary coproporphyria Hereditary gelsolin amyloidosis Heredofamilial amyloidosis Hunter syndrome Hurler syndrome (gargoylism, mucopolysaccharidosis type I) Hurler–Scheie syndrome (mucopolysaccharidosis type I H-S) Hyaluronidase deficiency (mucopolysaccharidosis type IX) Iatrogenic calcinosis cutis Idiopathic scrotal calcinosis (idiopathic calcified nodules of the scrotum) Lafora disease Lesch–Nyhan syndrome (juvenile gout) Lichen amyloidosis Limited joint mobility Lipoid proteinosis (hyalinosis cutis et mucosae, Urbach–Wiethe disease) Lipoprotein lipase deficiency (chylomicronemia, chylomicronemia syndrome) Macular amyloidosis Maroteaux–Lamy syndrome (mucopolysaccharidosis type VI) Medication-induced hyperlipoproteinemia Metastatic calcinosis cutis Milia-like calcinosis Morquio's disease (mucopolysaccharidosis type IV) Necrobiosis lipoidica (necrobiosis lipoidica diabeticorum) Niemann–Pick disease Nodular amyloidosis Nodular xanthoma Normolipoproteinemic xanthomatosis Obstructive liver disease (xanthomatous biliary cirrhosis) Ochronosis Osteoma cutis Palmar xanthoma Phenylketonuria Phytosterolemia (sitosterolemia) Porphyria cutanea tarda Primary cutaneous amyloidosis Primary systemic amyloidosis Prolidase deficiency Pseudoporphyria (pseudoporphyria cutanea tarda) Sanfilippo syndrome Scheie syndrome (mucopolysaccharidosis type I S) Secondary cutaneous amyloidosis Secondary systemic amyloidosis Sialidosis Sly syndrome (mucopolysaccharidosis type VII) Subepidermal calcified nodule (solitary congenital nodular calcification, Winer's nodular calcinosis) Transient erythroporphyria of infancy (purpuric phototherapy-induced eruption) Traumatic calcinosis cutis Tuberoeruptive xanthoma (tuberous xanthoma) Tumoral calcinosis Variegate porphyria (mixed hepatic porphyria, mixed porphyria, South African genetic porphyria, South African porphyria) Verruciform xanthoma Waxy skin Wilson's disease (hepatolenticular degeneration) Xanthelasma palpebrarum (xanthelasma) Xanthoma diabeticorum Xanthoma planum (plane xanthoma) Xanthoma striatum palmare Xanthoma tendinosum (tendinous xanthoma) Xanthoma tuberosum
=== Hyperinsulinemic hypoglycemia === Some mutations have been found to enhance insulin secretion. Heterozygosity for gain of function mutations reduces the threshold glucose that triggers insulin release. This creates hypoglycemia of varying patterns, including transient or persistent congenital hyperinsulinism, or fasting or reactive hypoglycemia appearing at an older age. The most recent overview of GCK mutation that were observed in patients claimed 17 GCK mutations to cause hyperinsulinemic hypoglycemia. Homozygosity for gain of function mutations has not been found.
The first Volunteer unit to be sent out was a 1,300 man composite battalion group, composed of infantry recruited from across London units and a field battery from the Honourable Artillery Company, the City Imperial Volunteers, which was raised in early January 1900; it was sent into combat after six weeks of training in South Africa, where Lord Roberts described it as "quite excellent", and was returned home in October. At the same time, a number of service companies were raised from volunteer units, employed as integral companies of their sister regular battalions, and were well regarded in the field. The decision was taken in late December to form a new force, the Imperial Yeomanry, to consist of mounted infantry. Whilst the Yeomanry provided many of the officers and NCOs, only a small number of the junior ranks came from existing Yeomanry regiments, with some more from Volunteer corps. The units performed well, but recruiting proceeded in fits and starts—recruitment stopped in May, and was only resumed in early 1901—and so an adequate supply of manpower was not always available. Sixty militia battalions, around 46,000 men, also volunteered and were eventually sent to South Africa. They were employed mainly on lines of communication, and regarded as second-line troops of low quality; this was unsurprising, as they were strongly deficient in officers, heavily composed of men of 18 and 19, who were regarded as too young by the Regular Army, with many of their best and most experienced men already deployed with regular units as members of the Militia Reserve.
== History == Some of the most important discoveries relating to transferases occurred as early as the 1930s. Earliest discoveries of transferase activity occurred in other classifications of enzymes, including beta-galactosidase, protease, and acid/base phosphatase. Prior to the realization that individual enzymes were capable of such a task, it was believed that two or more enzymes enacted functional group transfers.
In late 1999, al-Qaeda associate Walid bin Attash ("Khallad") contacted al-Mihdhar and told him to meet in Kuala Lumpur, Malaysia; al-Hazmi and Abu Bara al Yemeni would also be in attendance. The NSA intercepted a telephone call mentioning the meeting, al-Mihdhar, and the name "Nawaf" (al-Hazmi); while the agency feared "Something nefarious might be afoot", it took no further action. The CIA had already been alerted by Saudi intelligence about al-Mihdhar and al-Hazmi being al-Qaeda members. A CIA team broke into al-Mihdhar's Dubai hotel room and discovered that Mihdhar had a U.S. visa. While Alec Station alerted intelligence agencies worldwide, it did not share this information with the FBI. The Malaysian Special Branch observed the January 5, 2000, meeting of the two al-Qaeda members and informed the CIA that al-Mihdhar, al-Hazmi, and Khallad were flying to Bangkok, but the CIA never notified other agencies of this, nor did it ask the State Department to put al-Mihdhar on its watchlist. An FBI liaison asked permission to inform the FBI of the meeting but was told: "This is not a matter for the FBI."
Sources: en.wikipedia.org
Depending on the climatic conditions affecting crop yields, consumption and prices of agrochemicals are subject to wide fluctuations from year to year, also impacting the suppliers. The molecular structures of modern agrochemicals are much more complex than in older products, but lower than their pharma counterparts. The average molecular weight of the top 10 is 330, as compared with 477 for the top 10. In comparison to reagents used in pharmaceutical fine chemical syntheses, hazardous chemicals, including sodium azide, halogens, methyl sulfide, phosgene and phosphorus chlorides, are more frequently used. Agrochemical companies sometimes outsource just these steps, which require specialized equipment, on toll conversion deals. With exception of the pyrethroids, which are photostable modifications of naturally occurring pyrethrums, active ingredients of agrochemicals are rarely chiral. Examples within herbicides are Monsanto's round-up (glyphosate) and Syngenta's cyclohexadione-type mesotrione and paraquat dichloride. Within insecticides, the traditional organophosphates, like malathion, and pyrethroids, such as γ-cyhalotrin, are being substituted for by neonicotinoids, like Bayer's imidacloprid and Syngenta's thiamethoxam and pyrazoles, such as BASF's fipronil. Chloranthaniliprole is the most notable of Du Pont's anthranilic diamide family of broad spectrum insecticides. Within fungicides, the strobilurins, a new class, are growing rapidly and have already captured more than 30% of the $10 billion global fungicide market.
== Selected publications == Araujo JV, Davidenko N, Danner M, Cameron RE, Best SM: Novel Porous scaffolds of pH Responsive Chitosan/Carrageenan-based Polyelectrolyte Complexes for Tissue Engineering. J Biomed Mater Res A. 2014 Feb 14. Pawelec KM, Husmann A, Best SM, Cameron RE: Understanding anisotropy and architecture in ice-templated biopolymer scaffolds. Mater Sci Eng C Mater Biol Appl. 2014 Apr 1;37:141-7. Pawelec KM, Husmann A, Best SM, Cameron RE: A design protocol for tailoring ice-templated scaffold structure. J R Soc Interface. 2014 Jan 8;11(92):20130958. Shepherd JH, Ghose S, Kew SJ, Moavenian A, Best SM, Cameron RE: Effect of fiber crosslinking on collagen-fiber reinforced collagen-chondroitin-6-sulfate materials for regenerating load-bearing soft tissues. J Biomed Mater Res A. 2013 Jan;101(1):176-84. Kew SJ, Gwynne JH, Enea D, Brookes R, Rushton N, Best SM, Cameron RE: Synthetic collagen fascicles for the regeneration of tendon tissue. Acta Biomater. 2012 Oct;8(10):3723-31. Grover CN, Gwynne JH, Pugh N, Hamaia S, Farndale RW, Best SM, Cameron RE: Crosslinking and composition influence the surface properties, mechanical stiffness and cell reactivity of collagen-based films. Acta Biomater. 2012 Aug;8(8):3080-90. Grover CN, Farndale RW, Best SM, Cameron RE: The interplay between physical and chemical properties of protein films affects their bioactivity. J Biomed Mater Res A. 2012 Sep;100(9):2401-11.
==== Ovarian cancer ==== Healthy ovaries present in SHG a uniform epithelial layer and well-organized collagen in their stroma, whereas abnormal ones show an epithelium with large cells and a changed collagen structure. The r ratio (see #Orientational anisotropy) is also used to show that the alignment of fibrils is slightly higher for cancerous than for normal tissues.
=== Nucleic acids === The convention for a nucleic acid sequence is to list the nucleotides as they occur from the 5' end to the 3' end of the polymer chain, where 5' and 3' refer to the numbering of carbons around the ribose ring which participate in forming the phosphate diester linkages of the chain. Such a sequence is called the primary structure of the biopolymer.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.